The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ

European Urology

Volumn 42, Issue 6, 2002, Pages 570-576

  Bex, A ^a   Horenblas, S ^a   Meinhardt, W ^a   Verra, N ^a   De Gast, G C ^a   Mulders, P F A ^b   Zisman, Amnon ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NONE

Author keywords

Immunotherapy; Metastasis; Nephrectomy; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADULT; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MORBIDITY; NEPHRECTOMY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; FEASIBILITY STUDY; IMMUNOTHERAPY; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PILOT STUDY; PROSPECTIVE STUDY;

ADULT; CARCINOMA, RENAL CELL; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PATIENT SELECTION; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0036904921     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00404-9     Document Type: Article

References (27)

1. G.P. Haas B.G. Redman V.K. Rao E. Dybal J. Edson Pontes G.G. Hillman Immunotherapy for metastatic renal cell cancer: effect on the primary tumor J. Immunotherapy. 13 1993 130 135
2. J.R. Wagner M.M. Walther W.M. Linehan D.E. White S.A. Rosenberg J.C. Yang Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place J. Urol. 162 1999 43 45
3. W.F. Spencer W.M. Linehan M.M. Walther G.P. Haas M.T. Lotze S.L. Topalian Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study J. Urol. 147 1992 24 30
4. G.H. Mickisch A. Garin H. van Poppel L. de Prijck R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 9286 2001 966 970
5. R.C. Flanigan S.E. Salmon B.A. Blumenstein S.I. Bearman V. Roy P.C. McGrath Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell carcinoma N. Engl. J. Med. 345 23 2001 1655 1659
6. M.M. Walther R.B. Alexander G.H. Weiss D. Venzon A. Berman H.I. Pass Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma Urology 42 3 1993 250 257
7. M.M. Walther J.C. Yang H.I. Pass Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma J. Urol. 158 1997 1675 1678
8. R.T. Bennet S.E. Lerner H.C. Taub J.P. Dutcher J. Fleischmann Cytoreductive surgery for stage IV renal cell carcinoma J. Urol. 154 1995 32 34
9. P. Therasse S.G. Arbuck E.A. Eisenhauer J. Wanders R.S. Kaplan L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J. Natl. Cancer Inst. 92 3 2000 205 216
10. G.C. de Gast H.J. Klumpen F.A. Vyth-Dreese M.J. Kersten N.C. Verra J. Sein Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma Clin. Cancer. Res. 4 2000 1267 1272
11. K.A. Margolin Interleukin-2 in the treatment of renal cancer Semin. Oncol. 27 2 2000 194 203
12. R.M. Bukowski Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2 Cancer 80 1997 1198 1220
13. G. Fyfe R.I. Fisher S.A. Rosenberg M. Sznol D.R. Parkinson A. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J. Clin. Oncol. 13 1995 688 696
14. M.L. Fallick D.F. McDermott D. LaRock J.P. Long M.B. Atkins Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma J. Urol. 158 5 1997 1691 1695
15. A. Belldegrun O. Shvarts R.A. Figlin Expanding the indications for surgery and adjuvant interleukin-2 based immunotherapy in patients with advanced renal cell carcinoma Cancer J. Sci. Am. 6 Suppl 1 2000 88 92
16. J.R. Franklin R.A. Figlin J. Rauch B. Gitlitz A. Belldegrun Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience Semin. Urol. Oncol. 14 4 1996 230 236
17. M. Böhm A. Ittenson K.F. Schierbaum F.-W. Röhl S. Ansorge E.P. Allhoff Preatreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma Eur. Urol. 41 2002 458 468
18. V. Krishnamurthi A.C. Novick R.M. Bukowski Efficacy of multimodality therapy in advanced renal cell carcinoma Urology 51 6 1998 933 937
19. A. Sella D.A. Swanson J.Y. Ro J.B. Putnam R.J. Amato A.B. Markowitz Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma J. Urol. 149 1993 19 22
20. R.J. Motzer J. Bacik B.A. Murphy P. Russo M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 1 2002 289 296
21. G. Mickisch A. Garin H. van Poppel Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell-carcinoma: a randomised trial Lancet. 358 2001 966
22. R. Flanigan S. Salmon B. Blumenstein Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alonee for metastatic renal-cell cancer N Engl J Med 345 2001 1655
23. P.J. Elson R.S. Witte D.L. Trump Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma Cancer Res. 48 1988 7310
24. M.W. Kattan V. Reuter R.J. Motzer A postoperative prognostic nomogram for renal cell carcinoma J. Urol. 166 2001 63
25. R. Motzer M. Mazumbar J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J. Clin. Oncol. 17 1999 2530
26. A. Zisman A. Pantuck F. Dorey Improved prognostication of RCC using an Integrated Staging System (UISS) J. Clin. Oncol. 19 2001 1649
27. Han K, Zisman A, Wieder J. et al. Renal cell carcinoma and prognostic implication of metastatic sites. In: Proceedings of the 38th Annual Meeting of American Society of Clinical Oncology. Orlando, Florida. 2002.